TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* critically ill adults~* RASS score of -3 to 0 after receiving benzodiazepine therapy~* CAM-ICU positive~* no benzodiazepine therapy within the previous 12 hours~Exclusion Criteria:~1. contraindications to flumazenil including hypersensitivity~2. receipt of benzodiazepines for control of potentially life-threatening conditions (e.g., control of intracranial pressure or status epilepticus)~3. active seizure disorder or on current anti-convulsant therapy for history of seizure disorder. Seizures secondary to alcohol withdrawal will NOT be excluded.~4. history of traumatic brain injury complicated by seizures~5. acute episode (within prior 30 days) of severe traumatic brain injury~6. history of structural lesion (e.g. subarachnoid hemorrhage, cerebrovascular accident, intra-parenchymal hemorrhage) complicated by seizures~7. acute episode (within prior 14 days) of structural lesion (e.g. subarachnoid hemorrhage, cerebrovascular accident, intra-parenchymal hemorrhage)~8. brain tumor complicated by seizure~9. history of anoxic brain injury~10. third-degree burn with total body surface area (TBSA) burn greater than 20%~11. chronic benzodiazepine (clonazepam:lorazepam:diazepam approximately 4:8:40 mg per day) for 7 consecutive days with no taper~12. chronic delirium that is attributable to other causes~13. anticipated to transfer to lower level of care within 24 hours~14. admitted for polysubstance overdose as determined by initial drug toxicity screening~15. recent exposure (prior 7 days) to pro-convulsant medications (identified via medication list, medication reconciliation performed by PI/pharmacy medication reconciliation team, or urine drug screening)~16. children, incarcerated individuals, and pregnant women~17. unable to provide consent and the legally authorized representative is unable to provide consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Flumazenil Infusion (Type: ACTIVE_COMPARATOR): The flumazenil continuous infusion is started at an initial dose of 0.1 mg/hr., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
- Placebo Infusion (Type: PLACEBO_COMPARATOR): The placebo continuous infusion is started at an initial dose of 0.1 mg/hr (2 ml/hr)., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven adenocarcinoma of prostate with treatment of prostate cancer (radical prostatectomy, radiation therapy, etc.)~* had biochemical/clinical relapse and started on antiandrogens~* have documented history of hot flashes~Exclusion Criteria:~* History of MI, DVT, CVA~* peanut allergy~* untreated hypothyroidism~* must be off other medical treatment for hot flashes for 2 weeks before enrollment in this study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Subjects receive supplement
- 2 (Type: PLACEBO_COMPARATOR): Subjects will receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intra and Extra Oral Inspection of Oral Mucosa

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Registered dental hygienists members in the Swedish trade union~Exclusion criteria:~-

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- dental hygienists (Type: None): all dental hygienists members in the trade union for dental hygienists

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Flortaucipir 18F PET Imaging in BIOCARD Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females that have provided consent and are currently enrolled in BIOCARD study~* Ability to tolerate PET scan procedures~* Ability to provide informed consent for study procedures~Exclusion Criteria:~* Has condition(s) that could augment risk to participant or compromise ability to tolerate experimental procedures or interfere with analysis of the study data as determined by the investigator~* Has a history of risk factors for Torsades de Pointes or taking medications known to cause QT prolongation.~* Has electrocardiogram acquired prior to initial flortaucipir scan that clinically contradicts subject's participation in the study as determined by the investigator. Bazett's corrected QT (QTcB) interval must be assessed and not exceed accepted values (458 msec in males, 474 msec in females).~* Females of childbearing potential who are not surgically sterile, not refraining from sexual activity, or not using reliable contraceptive methods.~* Has hypersensitivity to flortaucipir~* Has a currently clinically significant infectious disease, endocrine/metabolic disease, pulmonary/renal/hepatic impairment, or cancer that could impact study participation or scan results in the opinion of the investigator.~* Has a non-study related radiopharmaceutical imaging/treatment procedure within seven days prior to flortaucipir imaging visit.~* Is unsuitable for a study of this type in the opinion of the investigator.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Amyloid Positive (Type: EXPERIMENTAL): Clinically normal amyloid positive subjects from BIOCARD study receiving a flortaucipir PET scan
- Amyloid Negative (Type: EXPERIMENTAL): Clinically normal amyloid negative subjects from BIOCARD study receiving a flortaucipir PET scan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Laparoscopic Appendicitis Score; a Multicenter Validation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients operated for the clinical suspicion of acute appendicitis that will undergo a diagnostic laparoscopy.~* Age ≥ 18 years.~* Written informed consent~Exclusion Criteria:~* Diagnostic laparoscopy and planned appendectomy for an appendectomy a froid.~* Primarily chosen for an open appendectomy.~* Not able to give informed consent (for example language barrier or legally incapable).~* Refused informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LAPP score (Type: OTHER): Use of the LAPP score during a diagnostic laparoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: JSP191 (Briquilimab) in Subjects With LR-MDS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* MDS with IPSS-R very low, low, or intermediate risk features~* Symptomatic cytopenias~* Women of childbearing potential (WOCBP) must agree to use an oral or implanted contraceptive, a double-barrier method of birth control, or an intrauterine device upon enrollment and through 3 months after receiving the last dose of JSP191~* Women not of childbearing potential must be post-menopausal (no menstrual period for a minimum of 12 months) or surgically sterilized and have a negative serum pregnancy test upon study entry~* Male subjects must be surgically sterile or willing to use contraception upon enrollment and through 3 months after receiving the last dose of JSP191~* Must be willing and able to provide informed consent~Exclusion Criteria:~* Anemia secondary to iron deficiency, vitamin B12 deficiency, or folate deficiency~* Prior allogeneic or autologous stem cell transplant~* Known history of human immunodeficiency virus (HIV) (no laboratory testing is required), or active infection with hepatitis B or hepatitis C~* Pregnant women or women who are nursing and do not wish to discontinue breastfeeding~* Any other medical condition that, in the opinion of the Investigator, could pose a significant safety risk to the subject or jeopardize the integrity of the study~* Subjects who, in the opinion of the Investigator, may not be able to comply with the requirements of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- JSP191 (Type: EXPERIMENTAL): This study will explore up to 5 ascending dose levels (Cohorts 1, 2, 3, 4, and 5) and subjects will receive JSP191 on Day 1 on each 8-week cycle for 4 consecutive cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy at-term parturients undergoing elective cesarean delivery under spinal anesthesia~Exclusion Criteria:~* Emergency cesarean delivery~* Respiratory disease~* significant comorbidities: preeclampsia, insulin-dependent diabetes mellitus~* obstructive sleep apnea~* body mass index \> 35kg/m2~* \<18yrs~* documented intolerance or allergy to systemic or neuraxial opioids~* patient with a history of chronic opioid or current use of opioids

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Hydromorphone 25mcg (Type: ACTIVE_COMPARATOR): The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
- Hydromorphone 50mcg (Type: ACTIVE_COMPARATOR): The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
- Hydromorphone 100mcg (Type: ACTIVE_COMPARATOR): The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Progesterone and Second Trimester Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Viable pregnancy~* Gestational age between 13 to 26 weeks~* Vaginal bleeding from uterine origin~* Singleton pregnancy~* Normal clotting tests~* Hemodynamically stable woman~Exclusion Criteria:~* Water leak~* Signs of preterm labor~* Fetal malformations incompatible with life~* Uterine malformations and other maternal conditions, i.e. liver disease, breast cancer, active thromboembolic state~* Past preterm birth

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Utrogestan (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High Flow Nasal Cannula vs Low Flow Oxygen Therapy in Bronchiolitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of bronchiolitis~* age \>28 days and \<6 months~* Oxygen saturation (SaO2) \<92%~* respiratory rate \>60 breaths/min~* dyspnea with respiratory distress assessment instrument (RDAI) score ≥8~* daily milk or food intake less than 2/3 than normally assumed~Exclusion Criteria:~* chronic diseases or syndromes~* respiratory diseases (i.e. bronchopulmonary dysplasia)~* heart diseases~* preterm birth (before 36 weeks of gestational age)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- High flow (Type: EXPERIMENTAL): High flow (2 L/kg/min) nasal cannula oxygen therapy
- Low flow (Type: ACTIVE_COMPARATOR): Low flow (max 3 L/min) oxygen therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Participants must be women age 45 or older and under age 75 at the time of study entry.~Participant must be scheduled for, or have intent to schedule, a screening mammogram.~Participant must be eligible for EA1151/TMIST. Participant must have declined participation in EA1151/TMIST. Participant must be able to complete questionnaires in English. Participant must have a U.S. zip code.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Women Who Decline TMIST (Type: None): Women who decline TMIST will be asked to fill out a survey with questions about demographics, income and employment, attitudes and experiences about COVID-19, and emotional well-being.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects aged 18 years and older~2. Primary FSGS based on renal biopsy findings consistent with FSGS and based on presentation of histopathology, medical history and clinical course OR subjects with genetic risk factors with presentations that are otherwise consistent with primary FSGS~3. Urinary total protein:creatinine ratio (UPCR) ≥ 3.5 g protein/g creatinine at screening~Exclusion Criteria:~1. Pregnant or nursing~2. History of organ transplantation, including renal transplantation~3. Currently on an organ transplant waiting list or there's a reasonable possibility of getting an organ transplant within 6 months of screening~4. Histological FSGS subtype of collapsing variant~5. Subjects who initiated, discontinued or changed dose of anti-CD20 monoclonal antibodies within 16 weeks (4 months) prior to screening are excluded. Subjects who initiated treatment with anti-CD20 monoclonal antibodies \>16 weeks (4 months) prior to screening are permitted if deemed safe by the investigator and only if they intend to remain on continued, unchanged therapy at a dosing interval that has been documented to achieve continuous B cell depletion for the given patient.~6. Subjects who discontinued Rituximab or other anti-CD20 monoclonal antibodies \>16 weeks (4 months) prior to screening without confirmed recovery of CD20+ B cell population to within normal range are excluded. Subjects who discontinued rituximab or other anti-CD20 monoclonal antibodies \>16 weeks (4 months) prior to screening with confirmed recovery of CD20+ B cell population to within normal range are permitted in the study. UPCR and other urine protein assessments up to 1 year prior to screening (if available) that were performed in these patients as part of the clinical routine should be recorded in the medical history.~7. Body Mass Index (BMI) ≥ 40

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequential (Type: EXPERIMENTAL): All enrolled subjects will initially be treated with the active study medication CCX140-B at a dose of 5 mg twice daily. Dose will increase in a step-wise fashion up to 15 mg twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Automatized Semi-Whole-Body-MRI Protocol for Cancer Staging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically indicated PET/CT for cancer staging or response assess-ment in patients with histopathologically confirmed solid tumors (e.g.prostate, breast, gastrointestinal, testicles)~* MRI can be scheduled within 1 week to PET/CT exam~Exclusion Criteria:~* general MRI contraindications (devices (e.g. certain pacemakers), pregnancy, claustrophobia)~* severely reduced general condition~* impaired renal function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oncologic patients (Type: OTHER): Oncologic patients with a previous PET/CT for whole-body staging

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Donors:~1. Age \>18 and \<65 years~2. Confirmed previous SARS CoV-2 infection~3. Signed informed consent to participate in this clinical trial, to donate plasma and to store the specimen for future testing.~4. At least 28 days from the end of isolation or resolution of symptoms of infection~5. Male donors, or female donors who have not been pregnant, or female donors who have been pregnant tested negative for HLA antibodies~6. Individuals who meet all regular voluntary donor eligibility requirements~Recipiants:~1. Signed informed consent to participate in this clinical trial.~2. Confirmed previous SARS CoV-2 infection~3. Respiratory distress with tachypnoe ≥30 breaths per minute,~4. Oxygen level less than 94% in resting-state,~5. Partial pressure of oxygen (PO2) ≤ 80 mmHg~Exclusion Criteria:~Donors:~1. Age : \<18 or \>65 years~2. Female subjects who are pregnant~3. HIV1,2 hepatitis B,C or syphilis infection~4. Donors ineligible for regular voluntary blood donation~Recipiants:~1. No informed consent to participate in the study~2. Patients with a history of plasma hypersensitivity, including anaphylactic shock in previous transfusions, allergic reactions to citrate or primary IgA deficiency~3. Patients with symptoms of severe multi-organ failure~4. Patients with known allergic reactions to chemical compounds used or generated in the procedure of inactivation of pathogens~5. Patients with active thrombosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hospitalized patients with SARS CoV-2 infection (Type: EXPERIMENTAL): Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Determine the Frequency of a HTPPE in 5 Years (± on 1 Year) After a First Episode of Idiopathic Pulmonary Embolism.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients having ended the study PADIS EP after the visit of the end of study and having signed the consent HTP.~Exclusion Criteria:~* Refusal to grant in writing to participate in the study PADIS HTP

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HTPPE (Type: OTHER): No drug and no placebo were used in this study. For all the patients who participated at the study PADIS-EP, somme exams must be performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues